Tobias Goeser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tobias Goeser has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
D Nierhoff
University of Cologne, Gastroenterology and Hepatology, Cologne
11 shared publicationsHm Steffen
Klinik für Gastroenterologie und Hepatologie des Universitätsklinikums Köln, Köln, Deutschland
9 shared publicationsA Bowe
University of Cologne, Department of Gastroenterology and Hepatology, Cologne, Germany
8 shared publicationsU Töx
Klinik für Gastroenterologie und Hepatologie des Universitätsklinikums Köln, Köln, Deutschland
8 shared publicationsU. Töx
8 shared publicationsH. M. Steffen
6 shared publications
Latest Publications
- Open Access
- 5 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2716
Comparison of Lactate Clearance with Established Risk Assessment Tools in Predicting Outcomes in Acute Upper Gastrointestinal Bleeding
Early risk stratification is mandatory in acute upper gastrointestinal bleeding (AUGIB) to guide optimal treatment. Numerous risk scores were introduced, but lack of practicability led to limited use in daily clinical practice. Lactate clearance is an established risk assessment tool in a variety of diseases, such as trauma and sepsis. Therefore, this study compares the predictive ability of pre-endoscopic lactate clearance and established risk scores in patients with AUGIB at the University Hospital of Cologne. Active bleeding was detected in 27 (25.2%) patients, and hemostatic intervention was performed in 35 (32.7%). In total, 16 patients (15%) experienced rebleeding and 12 (11.2%) died. Initially, lactate levels were elevated in 64 cases (59.8%), and the median lactate clearance was 18.7% (2.7–48.2%). Regarding the need for endoscopic intervention, the predictive ability of Glasgow Blatchford Score, pre-endoscopic Rockall score, initial lactate and lactate clearance did not differ significantly, and their area under the receiver operating characteristic curves were 0.658 (0.560–0.747), 0.572 (0.473–0.667), 0.572 (0.473–0.667) and 0.583 (0.483–0.677), respectively. Similar results were observed in relation to rebleeding and mortality. In conclusion, lactate clearance had comparable predictive ability compared to established risk scores. Further prospective research is necessary to clarify the potential role of lactate clearance as a reliable risk assessment tool in AUGIB.
- 5 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2716
Open AccessComparison of Lactate Clearance with Established Risk Assessment Tools in Predicting Outcomes in Acute Upper Gastrointestinal Bleeding
Early risk stratification is mandatory in acute upper gastrointestinal bleeding (AUGIB) to guide optimal treatment. Numerous risk scores were introduced, but lack of practicability led to limited use in daily clinical practice. Lactate clearance is an established risk assessment tool in a variety of diseases, such as trauma and sepsis. Therefore, this study compares the predictive ability of pre-endoscopic lactate clearance and established risk scores in patients with AUGIB at the University Hospital of Cologne. Active bleeding was detected in 27 (25.2%) patients, and hemostatic intervention was performed in 35 (32.7%). In total, 16 patients (15%) experienced rebleeding and 12 (11.2%) died. Initially, lactate levels were elevated in 64 cases (59.8%), and the median lactate clearance was 18.7% (2.7–48.2%). Regarding the need for endoscopic intervention, the predictive ability of Glasgow Blatchford Score, pre-endoscopic Rockall score, initial lactate and lactate clearance did not differ significantly, and their area under the receiver operating characteristic curves were 0.658 (0.560–0.747), 0.572 (0.473–0.667), 0.572 (0.473–0.667) and 0.583 (0.483–0.677), respectively. Similar results were observed in relation to rebleeding and mortality. In conclusion, lactate clearance had comparable predictive ability compared to established risk scores. Further prospective research is necessary to clarify the potential role of lactate clearance as a reliable risk assessment tool in AUGIB.
- Open Access
- 17 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5609
Perinatal Obesity Induces Hepatic Growth Restriction with Increased DNA Damage Response, Senescence, and Dysregulated Igf-1-Akt-Foxo1 Signaling in Male Offspring of Obese Mice
Maternal obesity predisposes for hepato-metabolic disorders early in life. However, the underlying mechanisms causing early onset dysfunction of the liver and metabolism remain elusive. Since obesity is associated with subacute chronic inflammation and accelerated aging, we test the hypothesis whether maternal obesity induces aging processes in the developing liver and determines thereby hepatic growth. To this end, maternal obesity was induced with high-fat diet (HFD) in C57BL/6N mice and male offspring were studied at the end of the lactation [postnatal day 21 (P21)]. Maternal obesity induced an obese body composition with metabolic inflammation and a marked hepatic growth restriction in the male offspring at P21. Proteomic and molecular analyses revealed three interrelated mechanisms that might account for the impaired hepatic growth pattern, indicating prematurely induced aging processes: (1) Increased DNA damage response (γH2AX), (2) significant upregulation of hepatocellular senescence markers (Cdnk1a, Cdkn2a); and (3) inhibition of hepatic insulin/insulin-like growth factor (IGF)-1-AKT-p38-FoxO1 signaling with an insufficient proliferative growth response. In conclusion, our murine data demonstrate that perinatal obesity induces an obese body composition in male offspring with hepatic growth restriction through a possible premature hepatic aging that is indicated by a pathologic sequence of inflammation, DNA damage, senescence, and signs of a possibly insufficient regenerative capacity.
- 17 May 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5609
Open AccessPerinatal Obesity Induces Hepatic Growth Restriction with Increased DNA Damage Response, Senescence, and Dysregulated Igf-1-Akt-Foxo1 Signaling in Male Offspring of Obese Mice
Maternal obesity predisposes for hepato-metabolic disorders early in life. However, the underlying mechanisms causing early onset dysfunction of the liver and metabolism remain elusive. Since obesity is associated with subacute chronic inflammation and accelerated aging, we test the hypothesis whether maternal obesity induces aging processes in the developing liver and determines thereby hepatic growth. To this end, maternal obesity was induced with high-fat diet (HFD) in C57BL/6N mice and male offspring were studied at the end of the lactation [postnatal day 21 (P21)]. Maternal obesity induced an obese body composition with metabolic inflammation and a marked hepatic growth restriction in the male offspring at P21. Proteomic and molecular analyses revealed three interrelated mechanisms that might account for the impaired hepatic growth pattern, indicating prematurely induced aging processes: (1) Increased DNA damage response (γH2AX), (2) significant upregulation of hepatocellular senescence markers (Cdnk1a, Cdkn2a); and (3) inhibition of hepatic insulin/insulin-like growth factor (IGF)-1-AKT-p38-FoxO1 signaling with an insufficient proliferative growth response. In conclusion, our murine data demonstrate that perinatal obesity induces an obese body composition in male offspring with hepatic growth restriction through a possible premature hepatic aging that is indicated by a pathologic sequence of inflammation, DNA damage, senescence, and signs of a possibly insufficient regenerative capacity.
- Open Access
- 4 May 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 24 (7) , 533-546
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Purpose of Review: Patients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabolic syndrome, represent a population at high cardiovascular risk and frequently suffer from atherogenic dyslipidemia. This article reviews the pathogenic interrelationship between NAFLD and dyslipidemia, elucidates underlying pathophysiological mechanisms and focuses on management approaches for dyslipidemic patients with NAFLD. Recent Findings: Atherogenic dyslipidemia in patients with NAFLD results from hepatic and peripheral insulin resistance along with associated alterations of hepatic glucose and lipoprotein metabolism, gut dysbiosis, and genetic factors. Summary: Since atherogenic dyslipidemia and NAFLD share a bi-directional relationship and are both major driving forces of atherosclerotic cardiovascular disease (ASCVD) development, early detection and adequate treatment are warranted. Thus, integrative screening and management programs are urgently needed. A stepwise approach for dyslipidemic patients with NAFLD includes (i) characterization of dyslipidemia phenotype, (ii) individual risk stratification, (iii) definition of treatment targets, (iv) lifestyle modification, and (v) pharmacotherapy if indicated.
- 4 May 2022
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 24 (7) , 533-546
Open AccessManagement of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Purpose of Review: Patients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabolic syndrome, represent a population at high cardiovascular risk and frequently suffer from atherogenic dyslipidemia. This article reviews the pathogenic interrelationship between NAFLD and dyslipidemia, elucidates underlying pathophysiological mechanisms and focuses on management approaches for dyslipidemic patients with NAFLD. Recent Findings: Atherogenic dyslipidemia in patients with NAFLD results from hepatic and peripheral insulin resistance along with associated alterations of hepatic glucose and lipoprotein metabolism, gut dysbiosis, and genetic factors. Summary: Since atherogenic dyslipidemia and NAFLD share a bi-directional relationship and are both major driving forces of atherosclerotic cardiovascular disease (ASCVD) development, early detection and adequate treatment are warranted. Thus, integrative screening and management programs are urgently needed. A stepwise approach for dyslipidemic patients with NAFLD includes (i) characterization of dyslipidemia phenotype, (ii) individual risk stratification, (iii) definition of treatment targets, (iv) lifestyle modification, and (v) pharmacotherapy if indicated.
- Open Access
Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1α Axis in the Offspring of Obese Mothers
Maternal obesity is associated with an increased risk of hepatic metabolic dysfunction for both mother and offspring and targeted interventions to address this growing metabolic disease burden are urgently needed. This study investigates whether maternal exercise (ME) could reverse the detrimental effects of hepatic metabolic dysfunction in obese dams and their offspring while focusing on the AMP-activated protein kinase (AMPK), representing a key regulator of hepatic metabolism. In a mouse model of maternal western-style-diet (WSD)-induced obesity, we established an exercise intervention of voluntary wheel-running before and during pregnancy and analyzed its effects on hepatic energy metabolism during developmental organ programming. ME prevented WSD-induced hepatic steatosis in obese dams by alterations of key hepatic metabolic processes, including activation of hepatic ß-oxidation and inhibition of lipogenesis following increased AMPK and peroxisome-proliferator-activated-receptor-γ-coactivator-1α (PGC-1α)-signaling. Offspring of exercised dams exhibited a comparable hepatic metabolic signature to their mothers with increased AMPK-PGC1α-activity and beneficial changes in hepatic lipid metabolism and were protected from WSD-induced adipose tissue accumulation and hepatic steatosis in later life. In conclusion, this study demonstrates that ME provides a promising strategy to improve the metabolic health of both obese mothers and their offspring and highlights AMPK as a potential metabolic target for therapeutic interventions.
Open AccessMaternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1α Axis in the Offspring of Obese Mothers
Maternal obesity is associated with an increased risk of hepatic metabolic dysfunction for both mother and offspring and targeted interventions to address this growing metabolic disease burden are urgently needed. This study investigates whether maternal exercise (ME) could reverse the detrimental effects of hepatic metabolic dysfunction in obese dams and their offspring while focusing on the AMP-activated protein kinase (AMPK), representing a key regulator of hepatic metabolism. In a mouse model of maternal western-style-diet (WSD)-induced obesity, we established an exercise intervention of voluntary wheel-running before and during pregnancy and analyzed its effects on hepatic energy metabolism during developmental organ programming. ME prevented WSD-induced hepatic steatosis in obese dams by alterations of key hepatic metabolic processes, including activation of hepatic ß-oxidation and inhibition of lipogenesis following increased AMPK and peroxisome-proliferator-activated-receptor-γ-coactivator-1α (PGC-1α)-signaling. Offspring of exercised dams exhibited a comparable hepatic metabolic signature to their mothers with increased AMPK-PGC1α-activity and beneficial changes in hepatic lipid metabolism and were protected from WSD-induced adipose tissue accumulation and hepatic steatosis in later life. In conclusion, this study demonstrates that ME provides a promising strategy to improve the metabolic health of both obese mothers and their offspring and highlights AMPK as a potential metabolic target for therapeutic interventions.
- Open Access
- 13 March 2021
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 30 (1) , 66-72
Environmental and Dietary Risk Factors for Colonic Diverticulosis and Diverticulitis
Background and Aims: Colonic diverticulosis (CD) is among the most common conditions of the large bowel. Several factors have been associated with an increased risk of CD and its complications, including advanced age, obesity, physical inactivity, and a low-fiber diet. Available data is conflicting and a comprehensive analysis of different bowel, dietary and environmental habits linked with CD is lacking. We aimed to investigate the relationship between potential risk factors and CD prevalence using full data from a colonoscopy-based cross-sectional study in Europe. Methods: The study was conducted at three tertiary referral centers in Germany and Lithuania. It included consecutive adult patients referred for routine colonoscopy who completed a detailed questionnaire on our considered multiple risk factors for diverticulosis and diverticulitis, including dietary and environmental factors, and bowel habits. Results: The study included 1,333 patients, 696 women and 635 men. Colonic diverticulosis was diagnosed in 858 (64%) of patients. Multivariate analysis revealed that age (OR: 1.08, 95%CI: 1.06–1.10, p<0.001) and obesity (OR: 1.05, 95%CI: 1.02–1.09, p=0.004) were associated with CD. We also revealed new risk factors for CD: increased frequency of bowel movements (OR: 0.10, 95%CI: 0.03-0.33, p<0.001) and feeling of incomplete bowel emptying (OR: 2.05, 95%CI: 1.47–2.87, p<0.001). Older participants had reduced odds (OR: 0.921, 95 CI: 0.89–0.95, p<0.05) of diverticulitis compared to younger subjects. Feeling of incomplete bowel emptying after defecation was associated with increased odds (OR: 2.769, 95% CI 1.35–5.7, p<0.006) for diverticulitis. Moreover, participants with a higher educational status had increased odds (OR: 2.453, 95%CI: 1.31–4.59, p=0.005) for diverticulitis compared to the lower education group. Conclusions: Study shows that older age, obesity, frequency of bowel movements, and feeling of incomplete bowel emptying are associated with the risk of CD. Furthermore, older age, feeling of incomplete bowel emptying, and higher education were associated with the risk of diverticulitis among CD patients.
- 13 March 2021
- Published by Romanian Society of Gastroenterology and Hepatology in Journal of Gastrointestinal and Liver Diseases
- Vol. 30 (1) , 66-72
Open AccessEnvironmental and Dietary Risk Factors for Colonic Diverticulosis and Diverticulitis
Background and Aims: Colonic diverticulosis (CD) is among the most common conditions of the large bowel. Several factors have been associated with an increased risk of CD and its complications, including advanced age, obesity, physical inactivity, and a low-fiber diet. Available data is conflicting and a comprehensive analysis of different bowel, dietary and environmental habits linked with CD is lacking. We aimed to investigate the relationship between potential risk factors and CD prevalence using full data from a colonoscopy-based cross-sectional study in Europe. Methods: The study was conducted at three tertiary referral centers in Germany and Lithuania. It included consecutive adult patients referred for routine colonoscopy who completed a detailed questionnaire on our considered multiple risk factors for diverticulosis and diverticulitis, including dietary and environmental factors, and bowel habits. Results: The study included 1,333 patients, 696 women and 635 men. Colonic diverticulosis was diagnosed in 858 (64%) of patients. Multivariate analysis revealed that age (OR: 1.08, 95%CI: 1.06–1.10, p<0.001) and obesity (OR: 1.05, 95%CI: 1.02–1.09, p=0.004) were associated with CD. We also revealed new risk factors for CD: increased frequency of bowel movements (OR: 0.10, 95%CI: 0.03-0.33, p<0.001) and feeling of incomplete bowel emptying (OR: 2.05, 95%CI: 1.47–2.87, p<0.001). Older participants had reduced odds (OR: 0.921, 95 CI: 0.89–0.95, p<0.05) of diverticulitis compared to younger subjects. Feeling of incomplete bowel emptying after defecation was associated with increased odds (OR: 2.769, 95% CI 1.35–5.7, p<0.006) for diverticulitis. Moreover, participants with a higher educational status had increased odds (OR: 2.453, 95%CI: 1.31–4.59, p=0.005) for diverticulitis compared to the lower education group. Conclusions: Study shows that older age, obesity, frequency of bowel movements, and feeling of incomplete bowel emptying are associated with the risk of CD. Furthermore, older age, feeling of incomplete bowel emptying, and higher education were associated with the risk of diverticulitis among CD patients.
- Open Access
- 4 February 2019
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 1-6
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
Carcinomas of the small bowel are rare tumors usually with dismal prognosis. Most recently, some potentially treatable molecular alterations were described. We emphasize the growing evidence of individualized treatment options in small bowel carcinoma. We performed a DNA- based multi-gene panel using ultra-deep sequencing analysis (including 14 genes with up to 452 amplicons in total; KRAS, NRAS, HRAS, BRAF, DDR2, ERBB2, KEAP1, NFE2L2, PIK3CA, PTEN, RHOA, BRCA1, BRCA2 and TP53) as well as an RNA-based gene fusion panel including ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, RET and ROS1 on eleven formalin fixed and paraffin embedded small bowel carcinomas. Additionally, mismatch-repair-deficiency was analyzed by checking the microsatellite status using the five different mononucleotide markers BAT25, BAT26, NR-21, NR-22 and NR-27 and loss of mismatch repair proteins using four different markers (MLH1, MSH6, MSH2, PMS2). In five out of eleven small bowel carcinomas we found potentially treatable genetic alterations. Three patients demonstrated pathogenic (class 5) BRCA1 or BRCA2 mutations – one germline-related in a mixed neuroendocrine-non neuroendocrine neoplasm (MiNEN). Two additional patients revealed an activating ERBB2 mutation or PIK3CA mutation. Furthermore two tumors were highly microsatellite-instable (MSI-high), in one case associated to Lynch-syndrome. We did not find any gene fusions. Our results underscore, in particular, the relevance of potentially treatable molecular alterations (like ERBB2, BRCA and MSI) in small bowel carcinomas. Further studies are needed to proof the efficacy of these targeted therapies in small bowel carcinomas.
- 4 February 2019
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 1-6
Open AccessAlterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
Carcinomas of the small bowel are rare tumors usually with dismal prognosis. Most recently, some potentially treatable molecular alterations were described. We emphasize the growing evidence of individualized treatment options in small bowel carcinoma. We performed a DNA- based multi-gene panel using ultra-deep sequencing analysis (including 14 genes with up to 452 amplicons in total; KRAS, NRAS, HRAS, BRAF, DDR2, ERBB2, KEAP1, NFE2L2, PIK3CA, PTEN, RHOA, BRCA1, BRCA2 and TP53) as well as an RNA-based gene fusion panel including ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, RET and ROS1 on eleven formalin fixed and paraffin embedded small bowel carcinomas. Additionally, mismatch-repair-deficiency was analyzed by checking the microsatellite status using the five different mononucleotide markers BAT25, BAT26, NR-21, NR-22 and NR-27 and loss of mismatch repair proteins using four different markers (MLH1, MSH6, MSH2, PMS2). In five out of eleven small bowel carcinomas we found potentially treatable genetic alterations. Three patients demonstrated pathogenic (class 5) BRCA1 or BRCA2 mutations – one germline-related in a mixed neuroendocrine-non neuroendocrine neoplasm (MiNEN). Two additional patients revealed an activating ERBB2 mutation or PIK3CA mutation. Furthermore two tumors were highly microsatellite-instable (MSI-high), in one case associated to Lynch-syndrome. We did not find any gene fusions. Our results underscore, in particular, the relevance of potentially treatable molecular alterations (like ERBB2, BRCA and MSI) in small bowel carcinomas. Further studies are needed to proof the efficacy of these targeted therapies in small bowel carcinomas.
- 13 August 2018
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 56 (08) , e368
Erfassung des leitliniengemäßgen Umgangs von Thrombozytenaggregationshemmern und oralen Antikoagulanzien bei Patienten mit nichtvariköser oberer gastrointestinaler Blutung
Einleitung: Die europäische Gesellschaft für gastrointestinale Endoskopie (ESGE) gibt in ihrer Leitlinie zur nichtvarikösen oberen gastrointestinalen Blutung (NVOGIB) Empfehlungen zum Umgang mit Thrombozytenaggregationshemmern (TAH) und oralen Antikoagulantien (OAK). Ziele: Erfassung eines leitlinengemäßen Umgangs mit TAH und OAK. Methodik: Retrospektive Analyse von Patienten mit einer endoskopisch diagnostizierten NVOGIB und vorheriger TAH- oder OAK-Exposition an einem deutschen Universitätsklinikum zwischen 01.01.2016 und 31.12.2017. Leitlinienentsprechendes Vorgehen wurde vereinfacht wie folgt definiert: 1. THA in Primärprophylaxe sollte abgesetzt werden. 2. THA in Sekundärprophylaxe sollte bei Hochrisikostigmata temporär pausiert und bei Niedrigrisikostigmata unverändert fortgeführt werden. 3. Duale TAH sollte bei Hochrisikostigmata und niedrigem Thromboserisiko pausiert und nur niedrig dosiertes ASS fortgeführt, bei hohem Thromboserisiko (akutes Koronarsyndrom < 12 Monate, elektiver BMS < 4 Wochen, DES < 6 Monate) und bei Niedrigrisikostigmata unverändert fortgeführt werden. 4. OAK sollte nach Unterbrechung innerhalb von 15 Tagen wieder begonnen worden. Forrest Ia, Ib, IIa und IIb wurden als Hochrisikostigmata, Forrest IIc und III als Niedrigrisikostigmata definiert. Ergebnis: 316 Patienten (68,4% männlich, medianes Alter 70,5 Jahre, Interquartilen Rangen 62 – 78) erfüllten die Einschlusskriterien. Der Umgang mit TAH in Primär- und Sekundärprophylaxe wurde in 37/83 Patienten (45%) als nicht leitlinienentsprechend klassifiziert. Alter, Geschlecht, behandelnde Fachrichtung, Majorblutung (Hb ≤8 g/dl, Hb-Abfall ≥2 g/dl, Transfusionsbedarf), Gabe von Blutprodukten, Charlson-Comorbidity-Index, Behandlung auf Intensivstation, Reendoskopie, Reblutung und endoskopische Stigmata waren hiermit nicht signifikant assoziiert. Bei 68/127 Patienten (53,5%) mit OAK und bei 61/127 Patienten (48%) nach zusätzlichem Einschluss von Heparin in therapeutischer Dosierung wurde der Umgang als nicht leitlinienentsprechend klassifiziert. Alter und behandelnde Fachdisziplin waren hiermit signifikant assoziiert. Schlussfolgerung: In einer signifikanten Anzahl der Patienten mit NVOGIB erfolgte der Umgang mit TAH und OAK nicht entsprechend den aktuellen ESGE-Empfehlungen.
- 13 August 2018
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 56 (08) , e368
Erfassung des leitliniengemäßgen Umgangs von Thrombozytenaggregationshemmern und oralen Antikoagulanzien bei Patienten mit nichtvariköser oberer gastrointestinaler Blutung
Einleitung: Die europäische Gesellschaft für gastrointestinale Endoskopie (ESGE) gibt in ihrer Leitlinie zur nichtvarikösen oberen gastrointestinalen Blutung (NVOGIB) Empfehlungen zum Umgang mit Thrombozytenaggregationshemmern (TAH) und oralen Antikoagulantien (OAK). Ziele: Erfassung eines leitlinengemäßen Umgangs mit TAH und OAK. Methodik: Retrospektive Analyse von Patienten mit einer endoskopisch diagnostizierten NVOGIB und vorheriger TAH- oder OAK-Exposition an einem deutschen Universitätsklinikum zwischen 01.01.2016 und 31.12.2017. Leitlinienentsprechendes Vorgehen wurde vereinfacht wie folgt definiert: 1. THA in Primärprophylaxe sollte abgesetzt werden. 2. THA in Sekundärprophylaxe sollte bei Hochrisikostigmata temporär pausiert und bei Niedrigrisikostigmata unverändert fortgeführt werden. 3. Duale TAH sollte bei Hochrisikostigmata und niedrigem Thromboserisiko pausiert und nur niedrig dosiertes ASS fortgeführt, bei hohem Thromboserisiko (akutes Koronarsyndrom < 12 Monate, elektiver BMS < 4 Wochen, DES < 6 Monate) und bei Niedrigrisikostigmata unverändert fortgeführt werden. 4. OAK sollte nach Unterbrechung innerhalb von 15 Tagen wieder begonnen worden. Forrest Ia, Ib, IIa und IIb wurden als Hochrisikostigmata, Forrest IIc und III als Niedrigrisikostigmata definiert. Ergebnis: 316 Patienten (68,4% männlich, medianes Alter 70,5 Jahre, Interquartilen Rangen 62 – 78) erfüllten die Einschlusskriterien. Der Umgang mit TAH in Primär- und Sekundärprophylaxe wurde in 37/83 Patienten (45%) als nicht leitlinienentsprechend klassifiziert. Alter, Geschlecht, behandelnde Fachrichtung, Majorblutung (Hb ≤8 g/dl, Hb-Abfall ≥2 g/dl, Transfusionsbedarf), Gabe von Blutprodukten, Charlson-Comorbidity-Index, Behandlung auf Intensivstation, Reendoskopie, Reblutung und endoskopische Stigmata waren hiermit nicht signifikant assoziiert. Bei 68/127 Patienten (53,5%) mit OAK und bei 61/127 Patienten (48%) nach zusätzlichem Einschluss von Heparin in therapeutischer Dosierung wurde der Umgang als nicht leitlinienentsprechend klassifiziert. Alter und behandelnde Fachdisziplin waren hiermit signifikant assoziiert. Schlussfolgerung: In einer signifikanten Anzahl der Patienten mit NVOGIB erfolgte der Umgang mit TAH und OAK nicht entsprechend den aktuellen ESGE-Empfehlungen.
- 13 August 2018
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 56 (08) , e312
Keine signifikante Verbesserung des Gesamtüberlebens durch HCC-Surveillance – Daten aus einem tertiären Referenzzentrum in Deutschland
Einleitung und Ziele: Internationale Leitlinien empfehlen eine Surveillance des hepatozellulären Karzinoms (HCC) alle 6 Monate mittels Ultraschall bei Hochrisikopatienten mit chronischen Lebererkrankungen. Ziel hierbei ist die Erkennung des HCC in frühen, potentiell kurativen Stadien. Ziel unserer Studie war, den Effekt der HCC-Surveillance auf den klinischen Verlauf sowie das Gesamtüberleben in unserem Kollektiv zu untersuchen. Methodik: Wir analysierten retrospektiv die Daten von 401 HCC-Patienten mit chronischen Lebererkrankungen unterschiedlicher Ätiologie, welche sich im Zeitraum von 1997 und 2015 in der Klinik für Gastroenterologie und Hepatologie an der Uniklinik Köln vorgestellt haben. Es wurden zwei Gruppen gebildet: Gruppe 1 bestand aus Patienten, bei denen zur Erstvorstellung kein HCC bekannt war und welche vorher mindestens zwei Ultraschalluntersuchungen bekommen hatten (n = 111). Gruppe 2 schloss Patienten ein, welche sich bei Erstvorstellung bereits mit einem HCC präsentierten (n = 290). Die beiden Gruppen wurden hinsichtlich Patienten- und Krankheitscharakteristika, Lebertransplantationshäufigkeit und Gesamtüberleben verglichen. Ergebnisse: Die Hauptätiologie war die chronische Hepatitis-C-Infektion (39%); 75% der Patienten waren männlich. Die mediane Nachbeobachtungszeit in der Gruppe 1 lag bei 76 Monaten (Spanne 4 – 310 Monate). Zum Zeitpunkt der Erstdiagnose litten die Patienten der Gruppe 1häufiger an einer Leberzirrhose (96% vs. 78%; p < 0,001), hatten eine geringere mediane Tumorgröße (3,5 cm (Spanne 1 – 14 cm) vs. 4,5 cm (Spanne 1 – 20 cm); p < 0,001), erfüllten häufiger die Milan-Kriterien (73% vs. 46%; p < 0,001) und erhielten häufiger eine Lebertransplantation (33% vs. 10%). Insgesamt unterschieden sich die Gruppen jedoch nicht signifikant hinsichtlich des medianen Gesamtüberlebens ((14 Monate (Spanne 4 – 214 Monate) in Gruppe 1 vs. 12 Monate (Spanne 1 – 231 Monate) in Gruppe 2; n.s.). Schlussfolgerung: In unserer Studie war die HCC-Surveillance mit der Erkennung von früheren Tumorstadien assoziiert, dies resultierte jedoch nicht in einer signifikanten Verbesserung des Gesamtüberlebens. Weitere prospektive Langzeit-Untersuchungen sind erforderlich, um den Effekt der HCC-Surveillance auf das Gesamtüberleben zu klären.
- 13 August 2018
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 56 (08) , e312
Keine signifikante Verbesserung des Gesamtüberlebens durch HCC-Surveillance – Daten aus einem tertiären Referenzzentrum in Deutschland
Einleitung und Ziele: Internationale Leitlinien empfehlen eine Surveillance des hepatozellulären Karzinoms (HCC) alle 6 Monate mittels Ultraschall bei Hochrisikopatienten mit chronischen Lebererkrankungen. Ziel hierbei ist die Erkennung des HCC in frühen, potentiell kurativen Stadien. Ziel unserer Studie war, den Effekt der HCC-Surveillance auf den klinischen Verlauf sowie das Gesamtüberleben in unserem Kollektiv zu untersuchen. Methodik: Wir analysierten retrospektiv die Daten von 401 HCC-Patienten mit chronischen Lebererkrankungen unterschiedlicher Ätiologie, welche sich im Zeitraum von 1997 und 2015 in der Klinik für Gastroenterologie und Hepatologie an der Uniklinik Köln vorgestellt haben. Es wurden zwei Gruppen gebildet: Gruppe 1 bestand aus Patienten, bei denen zur Erstvorstellung kein HCC bekannt war und welche vorher mindestens zwei Ultraschalluntersuchungen bekommen hatten (n = 111). Gruppe 2 schloss Patienten ein, welche sich bei Erstvorstellung bereits mit einem HCC präsentierten (n = 290). Die beiden Gruppen wurden hinsichtlich Patienten- und Krankheitscharakteristika, Lebertransplantationshäufigkeit und Gesamtüberleben verglichen. Ergebnisse: Die Hauptätiologie war die chronische Hepatitis-C-Infektion (39%); 75% der Patienten waren männlich. Die mediane Nachbeobachtungszeit in der Gruppe 1 lag bei 76 Monaten (Spanne 4 – 310 Monate). Zum Zeitpunkt der Erstdiagnose litten die Patienten der Gruppe 1häufiger an einer Leberzirrhose (96% vs. 78%; p < 0,001), hatten eine geringere mediane Tumorgröße (3,5 cm (Spanne 1 – 14 cm) vs. 4,5 cm (Spanne 1 – 20 cm); p < 0,001), erfüllten häufiger die Milan-Kriterien (73% vs. 46%; p < 0,001) und erhielten häufiger eine Lebertransplantation (33% vs. 10%). Insgesamt unterschieden sich die Gruppen jedoch nicht signifikant hinsichtlich des medianen Gesamtüberlebens ((14 Monate (Spanne 4 – 214 Monate) in Gruppe 1 vs. 12 Monate (Spanne 1 – 231 Monate) in Gruppe 2; n.s.). Schlussfolgerung: In unserer Studie war die HCC-Surveillance mit der Erkennung von früheren Tumorstadien assoziiert, dies resultierte jedoch nicht in einer signifikanten Verbesserung des Gesamtüberlebens. Weitere prospektive Langzeit-Untersuchungen sind erforderlich, um den Effekt der HCC-Surveillance auf das Gesamtüberleben zu klären.
- Open Access
- 31 May 2018
- Published by Springer Nature in BMC Gastroenterology
- Vol. 18 (1) , 1-7
Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
Adenocarcinomas or combined adeno-neuroendocrine carcinomas (MANEC) of small bowel usually have a dismal prognosis with limited systemic therapy options. This is the first description of a patient showing a germline-related BRCA1 mutated MANEC of his ileum. The tumor presented a susceptibility to a combined chemotherapy and the PARP1-inhibitor olaparib. A 74-year old male patient presented with a metastasized MANEC of his ileum. Due to clinical symptoms his ileum-tumor and the single brain metastasis were removed. We verified the same pathogenic (class 5) BRCA1 mutation in different tumor locations. There was no known personal history of a previous malignant tumor. Nevertheless we identified his BRCA1 mutation as germline-related. A systemic treatment was started including Gemcitabine followed by selective internal radiotherapy (SIRT) to treat liver metastases and in the further course Capecitabine but this treatment finally failed after 9 months and all liver metastases showed progression. The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. All liver metastases demonstrated with significant tumor regression after 3 months and could be removed. In his most current follow up from December 2017 (25 months after his primary diagnosis) the patient is in a very good general condition without evidence for further metastases. We present first evidence of a therapy susceptible germline-related BRCA1 mutation in small bowel adeno-neuroendocrine carcinoma (MANEC). Our findings offer a personalized treatment option. The germline background was unexpected in a 74-year old man with no previously known tumor burden. We should be aware of the familiar background in tumors of older patients as well.
- 31 May 2018
- Published by Springer Nature in BMC Gastroenterology
- Vol. 18 (1) , 1-7
Open AccessTherapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel
Adenocarcinomas or combined adeno-neuroendocrine carcinomas (MANEC) of small bowel usually have a dismal prognosis with limited systemic therapy options. This is the first description of a patient showing a germline-related BRCA1 mutated MANEC of his ileum. The tumor presented a susceptibility to a combined chemotherapy and the PARP1-inhibitor olaparib. A 74-year old male patient presented with a metastasized MANEC of his ileum. Due to clinical symptoms his ileum-tumor and the single brain metastasis were removed. We verified the same pathogenic (class 5) BRCA1 mutation in different tumor locations. There was no known personal history of a previous malignant tumor. Nevertheless we identified his BRCA1 mutation as germline-related. A systemic treatment was started including Gemcitabine followed by selective internal radiotherapy (SIRT) to treat liver metastases and in the further course Capecitabine but this treatment finally failed after 9 months and all liver metastases showed progression. The treatment failure was the reason to induce an individualized therapeutic approach using combined chemotherapy of carboplatin, paclitaxel and the Poly (ADP-ribose) polymerase- (PARP)-inhibitor olaparib analogous to the treatment protocol of Oza et al. All liver metastases demonstrated with significant tumor regression after 3 months and could be removed. In his most current follow up from December 2017 (25 months after his primary diagnosis) the patient is in a very good general condition without evidence for further metastases. We present first evidence of a therapy susceptible germline-related BRCA1 mutation in small bowel adeno-neuroendocrine carcinoma (MANEC). Our findings offer a personalized treatment option. The germline background was unexpected in a 74-year old man with no previously known tumor burden. We should be aware of the familiar background in tumors of older patients as well.
- 27 March 2018
- Published by Georg Thieme Verlag KG
- Vol. 50 (04) , OP141
WIDE VARIATION IN DETECTION RATES OF CLINICALLY RELEVANT SERRATED POLYPS BETWEEN EXPERIENCED GASTROENTEROLOGISTS DURING AVERAGE-RISK SCREENING COLONOSCOPIES AND ANALYSIS OF FACTORS ASSOCIATED WITH THEIR DETECTION
Aims: Endoscopic detection and histopathological evaluation of serrated polyps (SP), which have been recognized as precursors of colorectal cancer (CRC) via the serrated pathway and which account for around 15% of all CRC cases, is challenging. Therefore, the new entity of clinically relevant SPs (crSPs) has recently been proposed. However, data on their prevalence are sparse. Methods: We retrospectively analysed average-risk screening colonoscopies performed at a tertiary academic hospital and 6 community-based private practices in Germany between 01/01/2012 and 14/12/2016. Exclusion criteria were age < 50 years, chronic inflammatory bowel disease, history of CRC, hereditary cancer syndromes, and incomplete procedures, e.g. failed cecal intubation. CrSPs were defined as SPs ≥10 mm and/or SPs > 5 mm located proximal to the splenic flexure. Conventional adenomas (cAD) were defined as adenomas excluding SPs. Results: A total of 4,161 colonoscopies from average-risk individuals were included (48.4% were men; median age was 62 years, interquartile range 56 – 69 years), performed by 15 experienced gastroenterologists. CrSPs were detected in 6.9% of all screening colonoscopies. The mean detection rate was 4.7% (95%-confidence interval 2.3 – 7.2%). Detection rates ranged from 0% to 16.2% between gastroenterologists. In a multivariate analysis only simultaneous detection of cAD, but not patient age and gender, was significantly associated with the detection of crSPs (odds ratio 1.784; 95%-confidence interval 1.384 – 2.298, p < 0.001). We also observed a moderate, but significant correlation between the individual endoscopist's detection rate for cAD and crSP (r = 0.541, p = 0.019). Conclusions: Detection rates for crSPs differed between participating endoscopists. However, individual skills to detect polypoid lesions has a relevant bearing on the detection rate of crSPs.
- 27 March 2018
- Published by Georg Thieme Verlag KG
- Vol. 50 (04) , OP141
WIDE VARIATION IN DETECTION RATES OF CLINICALLY RELEVANT SERRATED POLYPS BETWEEN EXPERIENCED GASTROENTEROLOGISTS DURING AVERAGE-RISK SCREENING COLONOSCOPIES AND ANALYSIS OF FACTORS ASSOCIATED WITH THEIR DETECTION
Aims: Endoscopic detection and histopathological evaluation of serrated polyps (SP), which have been recognized as precursors of colorectal cancer (CRC) via the serrated pathway and which account for around 15% of all CRC cases, is challenging. Therefore, the new entity of clinically relevant SPs (crSPs) has recently been proposed. However, data on their prevalence are sparse. Methods: We retrospectively analysed average-risk screening colonoscopies performed at a tertiary academic hospital and 6 community-based private practices in Germany between 01/01/2012 and 14/12/2016. Exclusion criteria were age < 50 years, chronic inflammatory bowel disease, history of CRC, hereditary cancer syndromes, and incomplete procedures, e.g. failed cecal intubation. CrSPs were defined as SPs ≥10 mm and/or SPs > 5 mm located proximal to the splenic flexure. Conventional adenomas (cAD) were defined as adenomas excluding SPs. Results: A total of 4,161 colonoscopies from average-risk individuals were included (48.4% were men; median age was 62 years, interquartile range 56 – 69 years), performed by 15 experienced gastroenterologists. CrSPs were detected in 6.9% of all screening colonoscopies. The mean detection rate was 4.7% (95%-confidence interval 2.3 – 7.2%). Detection rates ranged from 0% to 16.2% between gastroenterologists. In a multivariate analysis only simultaneous detection of cAD, but not patient age and gender, was significantly associated with the detection of crSPs (odds ratio 1.784; 95%-confidence interval 1.384 – 2.298, p < 0.001). We also observed a moderate, but significant correlation between the individual endoscopist's detection rate for cAD and crSP (r = 0.541, p = 0.019). Conclusions: Detection rates for crSPs differed between participating endoscopists. However, individual skills to detect polypoid lesions has a relevant bearing on the detection rate of crSPs.